Introduction
The interaction between leukocytes and renal resident cells may provide the key roles to the progression of the inflammatory processes. Moreover, leukocyte trafficking from peripheral blood into the diseased kidneys is a hallmark of almost any kind of renal diseases (1) . Activated leukocytes are thought to play a crucial role in the pathogenesis of renal diseases from acute phases to chronic phases (2) . Recent investigations of the pathophysiological roles of chemokines and their cognate receptors have shed light on the detailed molecular mechanisms of leukocyte trafficking and activation in various diseases (3) (4) (5) . In addition, these chemokines exert overlapping but distinct actions on specific cell types through interacting with the cognate G proteincoupled receptors with seven transmembrane domains (2) (3) (4) (5) . Chemokine receptors are expressed not only on leukocytes, but also parenchymal cells, suggesting the possible autocrine/paracrine loop during the interaction of leukocytes and parenchymal cells.
Therefore, detailed mechanisms of leukocyte recruitment and activation via chemokines/chemokine receptor systems may provide the better understanding of the pathogenesis of renal diseases. This review will focus on 1) chemokine/chemokine receptor systems in the pathogenesis of phase-specific renal disorders ("chemokine cascade"), and 2) the measurement of urinary levels of chemokines useful for monitoring the different disease phases and activities of human renal diseases, and 3) the intervention of chemokines/chemokine receptor systems as the particular immunotherapeutic strategies to combat with the specific phases of renal diseases.
reduced the renal expression of chemokines and their cognate receptors in accordance with the decrease in the clinical activities of human renal diseases (19) (20) (21) (22) (23) (24) (25) .
Chemokines/chemokine receptors in recent animal models

Lessons from gene targeting mice
Data from gene targeting mice can give rise to the identification of the actions of chemokines and their cognate receptors (2) . Accumulating data suggest that chemokines and their cognate receptors expressed in the diseased kidneys govern critical aspects of acute and chronic renal inflammation leading to glomerulosclerosis and interstitial fibrosis (2) . Lack of CCR1 enhanced Th1 responses and glomerular injury induced by the administration of nephrotoxic serum (26) . Considering the expression of CCR1 on mesangial cells (15) and the probable involvement of CCR1 in interstitial fibrosis (24) , CCR1 may protect glomerular and interstitial injury after the initial insults. On the other hand, anti CCR1 antibodies significantly reduced the accumulation of inflammatory cells and collagen deposition, resulting in dramatic improvement of survival in bleomycin-induced lung fibrosis in mice (27) . The identification of organ-and phase-specific roles of CCR1 will be required. Similarly, deleting MCP-1 dramatically reduces Mφ and T cell recruitment, protects kidney pathology, reduces proteinuria and prolongs survival in MCP-1-deficient MRL-Fas lpr mice (28) (29) . In contrast, the intensity of glomerulonephritis in CCR2 knockout mice was more severe induced by nephrotoxic serum.
This result suggests glomerulonephritis is not solely dependent on the presence of CCR2 for progression of disease and that the intriguing possibility that a CCR2 gene product ameliorates glomerulonephritis in this murine model. (30) . Further studies, therefore, will be required to identify the detailed molecular mechanisms of chemokine and chemokine receptor actions in renal diseases in vivo. 
Establishment of cell-mediated renal injury via ex-vivo gene transfer of chemokine
Chemokines in human renal diseases
Chemokine cascades
In inflammatory renal diseases, the types of leukocytes migrated to the diseased kidneys depend on the types of insults; neutrophils in acute inflammation, macrophages, lymphocytes and plasma cells in chronic inflammation, resulting in renal sclerosis/fibrosis. To clarify the mechanism of specific leukocyte infiltration into the diseased kidneys and the involvement of chemokines and their cognate receptors in renal diseases, both urinary and plasma levels of chemokines were measured in patients with various renal diseases at different phases. Firstly, urinary IL-8 levels were elevated in the acute phase and acute exacerbation of inflammatory renal diseases including IgA nephropathy, acute glomerulonephritis, lupus nephritis and crescentic glomerulonephritis (19) (20) . Urinary levels of IL-8 were correlated with glomerular endocapillary proliferation and the degree of hematuria (19) (20) . Elevated urinary IL-8 levels during the acute phase or exacerbation was found to be decreased during spontaneous or glucocorticoid therapy-induced convalescence in all patients examined.
Taken together, locally produced IL-8 in the diseased kidneys may reflect acute renal disease status based on leukocyte infiltration in the diseased kidneys (Table 1) .
Secondly, urinary MCP-1 levels were significantly higher in patients with advanced renal diseases, and were correlated with pathological progressive factors such as mesangial proliferation, crescentic formation and interstitial lesions associated with CD68 positive Mφ in patients with IgA nephropathy, lupus nephritis, crescentic glomerulonephritis and other inflammatory renal diseases (20, (22) (23) .
Urinary MCP-1 levels in lupus nephritis patients with active lesions were significantly higher than those with inactive lesions. Moreover, elevated urinary MCP-1 levels were dramatically decreased during steroid therapy-induced convalescence.
MCP-1 was mainly detected in vascular endothelial cells, tubular epithelial cells and infiltrated mononuclear cells in the interstitial lesions via both immunohistochemical
and in situ hybridization analyses (20, (22) (23) . Collectively, these observations suggest (Table 1) . Taken these together with the results in inflammatory renal diseases, up-regulation of MCP-1 may be a common regulatory pathway involved in the progressive renal damage with any etiologies leading to interstitial fibrosis (Figure 1) . Thus, the development of therapeutic approaches via MCP-1/its cognate receptors will be anticipated for the prevention of progressive renal injury in near future.
MCP-1: a common regulatory molecule of chronic inflammation resulting in
Crescentic glomerulonephritis: Th1 type immune responses
In rapidly progressive glomerulonephritis, crescentic glomerulonephritis, associated with a comparable degree of tubulointerstitial nephritis and anemia, is a prominent feature which leads to eventual loss of renal function (23) . 
Chemokines and Th2-type immune responses
Little is known about chemokines/chemokine receptors toward Th2 immune responses in kidney diseases (40) . Locally produced eotaxin, the cognate ligand for CCR3, may contribute to renal eosinophil infiltration in the interstitium and that the elevated urinary levels of eotaxin fell dramatically during the glucocorticoid-induced convalescence, suggesting that they may reflect disease activities (41) . Further investigations would be informative for our understanding of host immune responses and renal diseases based on Th1/Th2 immune responses.
Interstitial renal damage and chemokines
In addition to glomerular diseases, chemokines/chemokine receptor systems may be involved in interstitial renal diseases. Recently, fractalkine expressed in the interstitium was reported to be involved leukocyte influx including CD16 positive cells (25) . Although, the intervention of fractalkine receptor, CX3CR1 showed the prevention of glomerular damage with the decrease in leukocyte infiltration (42) , the blockade of fractalkine/its receptor may be beneficial to the prevention of interstitial damage as well as glomerular diseases. In addition, MCP-1, as anticipated, was involved in the interstitial nephritis (43) . MCP-1 and other C-C chemokines were involved in the pathogenesis of allograft rejection (44) . Interestingly, Met-RANTES reduced vascular and tubular damage during acute allograft rejection (45) .
Anti-chemokine therapy: novel therapeutic intervention to renal diseases
Based on in vitro and in vivo studies, selective intervention of chemokines/chemokine receptor systems and the adequate timing of anti-chemokine therapy may have the potential as the particular therapeutic strategies to combat with renal diseases culminating in renal sclerosis/fibrosis (46) .
Neutralizing antibodies against chemokines
The pathophysiological role of IL-8 was explored in animal model of acute 
p38 mitogen-activated kinases (MAPK) and chemokines
Mitogen-activated protein kinase (MAPK) signal transduction pathway is thought to be involved in proliferation and apoptosis in various types of inflammatory diseases (50) . The activation of MAPK isoform p38, detected also in mesangial cells is closely related to apoptosis, stress responses and inflammation (50) (51) . Moreover, the phosphorylation of p38 MAPK may contribute to the activation of nuclear factor (NF) κB and activating protein (AP) 1, which may be essentially involved in inflammatory processes. FR167653 dramatically decreased the phosphorylation of p38 MAPK in cultured rat mesangial cells stimulated by interleukin-1β (our unpublished data). The administration of FR167653 reduced glomerular damage, including crescentic formation and proteinuria (52) . In addition, FR167653 markedly decreased renal expression of MIP-1α and MCP-1. This study may provide evidence that p38 MAPK is a novel target for the therapy of glomerulonephritis.
Other approaches to chemokine /chemokine receptor systems
Agents that have impacts on cAMP (53) 
Concluding remarks and future directions
Based on the essential involvement of chemokine/chemokine receptor systems in the pathogenesis of phase-specific renal disorders, the intervention of Table 1 "Chemokine cascade", in which chemokines may explain particular clinical symptoms and pathological findings of renal diseases. 
